BioCryst Joins HCV Race With $101M Presidio Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
BioCryst’s proposed merger with Presidio will give the company an instant HCV pipeline. Albeit early-stage, the variety of the drugs could give the company a strong hand against other players in the field.